SNPHF (Santen Pharmaceutical Co) Other Long-Term Liabilities: $232 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNPHF Santen Pharmaceutical Co Ltd SNPHF
71 GF Score
Price $13.05
GF Value $10.47
Valuation Modestly Overvalued
View Full Analysis

What is Santen Pharmaceutical Co Other Long-Term Liabilities?

Santen Pharmaceutical Co SNPHF +4.40% 71 Other Long-Term Liabilities is $232 Mil as of Jun. 2026. GuruFocus rates SNPHF with a GF Score™ of 71/100 and a GF Value™ of $10.47 (Modestly Overvalued).

Santen Pharmaceutical Co's other long-term liabilities for the quarter that ended in Jun. 2026 was $232 Mil.

Santen Pharmaceutical Co's quarterly other long-term liabilities declined from Dec. 2025 ($267 Mil) to Mar. 2026 ($238 Mil) and declined from Mar. 2026 ($238 Mil) to Jun. 2026 ($232 Mil).

Santen Pharmaceutical Co's annual other long-term liabilities declined from Mar. 2024 ($242 Mil) to Mar. 2025 ($241 Mil) and declined from Mar. 2025 ($241 Mil) to Mar. 2026 ($238 Mil).

Santen Pharmaceutical Co Other Long-Term Liabilities Related Terms

Santen Pharmaceutical Co Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Other Long-Term Liabilities Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 221.24 277.61 241.91 240.96 237.54

Santen Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 277.10 274.53 266.99 237.54 231.90
SNPHF
71GF Score
Santen Pharmaceutical Co Ltd SNPHF
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $232 Mil mean?
Santen Pharmaceutical Co (SNPHF) has a Other Long-Term Liabilities of $232 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Other Long-Term Liabilities too high?
Santen Pharmaceutical Co's current Other Long-Term Liabilities is $232 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Other Long-Term Liabilities compare to LLY and JNJ?
Santen Pharmaceutical Co's Other Long-Term Liabilities of $232 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Other Long-Term Liabilities is $232 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.47, compared to a current price of $13.05 — trading 24.6% above its estimated fair value. The current Other Long-Term Liabilities is $232 Mil. Santen Pharmaceutical Co's overall GF Score™ is 71/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Other Long-Term Liabilities is $232 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 24.6% above its estimated GF Value™ of $10.47. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Other Long-Term Liabilities: $232 Mil
  • GF Value™: $10.47 vs. price of $13.05 (24.6% above fair value)
  • GF Score™: 71/100

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
71GF Score

Get the complete analysis for SNPHF

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.47
GF Value